Amneal Pharmaceuticals, Inc.
Extracted from this filing and checked against the source text.
Amneal Pharmaceuticals, Inc. shareholders approved Election of director nominees to hold office until the 2027 Annual Meeting at the 2026-05-06 meeting.
Proposal 1 : To elect the following director nominees to hold office until the 2027 Annual Meeting of Stockholders and until their respective successors are elected and qualified: For Against Abstain Broker Non-Votes Deb Autor 250,782,208 20,907,573 34,992 21,948,638 J. Kevin Buchi 247,071,067 24,615,560 38,146 21,948,638 Jeff George 250,652,568 21,032,093 40,112 21,948,638 John Kiely 239,969,127 31,717,386 38,260 21,948,638 Paul Meister 237,733,309 33,950,919 40,545 21,948,638 Ted Nark 265,399,266 6,285,254 40,253 21,948,638 Chintu Patel 270,365,045 1,320,024 39,704 21,948,638 Chirag Patel 270,364,571 1,320,525 39,677 21,948,638 Gautam Patel 270,643,127 1,042,157 39,489 21,948,638 Shlomo Yanai 250,631,212 21,053,488 40,073 21,948,638View on SEC.gov
Amneal Pharmaceuticals, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-06 meeting.
Proposal 3 : To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: For Against Abstain Broker Non-Votes 293,211,820 409,435 52,156 0View on SEC.gov
Amneal Pharmaceuticals, Inc. shareholders approved Advisory vote on the compensation of the Company's named executive officers at the 2026-05-06 meeting.
Proposal 2 : To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers: For Against Abstain Broker Non-Votes 269,089,785 2,577,481 57,507 21,948,638View on SEC.gov
63 shareholder votes filed in the last 30 days. Browse all shareholder votes →
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.